Recent News
- SemaThera Board Names Garth Cumberlidge as President & CEO November 1, 2018
- Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience August 12, 2018
- SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan March 21, 2018
- AmorChem spins out its SEMA 3A technology into SemaThera, with 1m$ seed investment January 11, 2017